Biolife Solutions INC Form 4 insider transactions

Catherine Coste, a director of BioLife Solutions, acquired 5,701 shares of common stock on March 18, 2025, according to a Form 4 filing with the SEC.

Anthony Hunt, a director at BioLife Solutions, acquired 6,876 shares of common stock on March 18, 2025, under the company's 2023 Performance Incentive Plan.

Director Timothy L. Moore reports acquisition of 6,876 shares of BioLife Solutions Inc. common stock on March 18, 2025.

Karen A. Foster, Chief Quality and Operations Officer of BioLife Solutions, reports the acquisition of common stock grants as part of her compensation.

Director Rachel Ellingson reports acquiring 6,876 shares of BioLife Solutions common stock on March 18, 2025, bringing her total direct holdings to 49,825 shares.

Sarah Aebersold, Chief Human Resources Officer of BioLife Solutions, files an amendment to a previous Form 4 to correct the number of shares sold on March 17, 2025.

EVP and Chief Scientific Officer of BioLife Solutions, Aby J. Mathew, reports the acquisition of common stock through restricted stock grants.

Todd Berard, Chief Marketing Officer of BioLife Solutions, reports the acquisition of common stock grants as part of compensation.

Troy Wichterman, CFO of BioLife Solutions, reports the acquisition of common stock through restricted stock grants as part of the company's incentive plans.

Director Joydeep Goswami reports acquiring 6,876 shares of BioLife Solutions common stock on March 18, 2025, bringing his total holdings to 47,986 shares.

Sean Werner, Chief Technology Officer of BioLife Solutions Inc., reports acquiring 22,919 shares of common stock on March 18, 2025, as part of his 2025 compensation.

Roderick de Greef, President and CEO of BioLife Solutions, reports acquiring 112,835 shares of common stock on March 18, 2025, according to a Form 4 filing with the SEC.

Sarah Aebersold, Chief Human Resources Officer of BioLife Solutions, sold a portion of her common stock holdings under a pre-arranged Rule 10b5-1 trading plan.

Todd Berard, Chief Marketing Officer of BioLife Solutions, sold 1,577 shares of common stock on March 11, 2025, to cover tax obligations related to vesting restricted stock.

Sarah Aebersold, Chief Human Resources Officer of BioLife Solutions, sold shares of common stock under pre-arranged 10b5-1 trading plans.

Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions Inc., sold 1,597 shares of common stock on March 11, 2025, to cover tax withholding obligations related to vesting restricted stock.

Karen A. Foster, Chief Quality and Operations Officer of BioLife Solutions, sold 1,331 shares of common stock on March 11, 2025, at a price of $25 per share to cover tax obligations related to vesting restricted stock.

Troy Wichterman, CFO of BioLife Solutions, sold 4,151 shares of common stock on March 11, 2025, to cover tax withholding obligations related to vesting restricted stock.

Sean Werner, Chief Technology Officer of BioLife Solutions, sold shares of common stock on March 3rd and 4th, 2025, to satisfy tax withholding obligations related to vesting restricted stock.

Karen A. Foster, Chief Quality and Operations Officer of BioLife Solutions, sold 324 shares of common stock on March 3, 2025, to cover tax withholding obligations related to vesting restricted stock.

Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions Inc., sold 425 shares of common stock on March 3, 2025, to cover tax withholding obligations related to vesting restricted stock.

Troy Wichterman, CFO of BioLife Solutions, sold 660 shares of common stock on March 3, 2025, at a price of $25.46 per share to cover tax withholding obligations related to vesting restricted stock.

Sarah Aebersold, Chief Human Resources Officer of BioLife Solutions, sold 284 shares of common stock on March 3, 2025, to cover tax withholding obligations related to vesting restricted stock.

Todd Berard, Chief Marketing Officer of BioLife Solutions, sold 424 shares of common stock on March 3, 2025, to satisfy tax withholding obligations related to vesting restricted stock.

Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions Inc., sold 92 shares of common stock on February 12, 2025, to satisfy tax withholding obligations related to vesting restricted stock.

Troy Wichterman, CFO of BioLife Solutions, sold 159 shares of common stock on February 12, 2025, to satisfy tax withholding obligations related to vesting restricted stock.

Karen A. Foster, Chief Quality and Operations Officer of BioLife Solutions Inc., sold 78 shares of common stock on February 12, 2025, to cover tax withholding obligations related to vesting restricted stock.

Todd Berard, Chief Marketing Officer of BioLife Solutions, sold 102 shares of common stock on February 12, 2025, to cover tax withholding obligations related to vesting restricted stock.

Sarah Aebersold, Chief Human Resources Officer of BioLife Solutions, sold 53 shares of common stock on February 12, 2025, to cover tax withholding obligations related to vesting restricted stock.

Sarah Aebersold, Chief Human Resources Officer at BioLife Solutions, sold 240 shares of common stock at $27.02 per share under a pre-arranged 10b5-1 trading plan.